Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good for you, going public with your scatology fetish.
Are you following some kind of 12-step program, where post #326080 was your rock-bottom point? Because that was sickening. I used the word "feces" in an analogy about chimpanzees in the zoo. You, however.... well, let's read it again:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173717054
I think they are describing their two different products on that same instruction sheet.
full price version: 720 hours, can be turned ON/OFF
trial version: 168 hours (7-days), cannot be turned ON/OFF
you bought the full-price version.
You can add more adjectives to describe how KT Tape mishandled Wave, and you can add adjectives to describe how every other distributor and country and government and organization and retailer mishandled the ActiPatch, but BIEL is solely to blame for the lack of BIEL revenues.
High hopes were pinned on KT Tape, but that's not their fault. From KT Tape's perspective, they didn't mishandle the Wave -- they picked a price point and design, and if it sold, fine, but if it failed, oh well, minimal loss, minimal risk. Maybe the product was "Mishandled" from the viewpoint of BIEL shareholders with unrealistic expectations, but that's not KT Tape's fault -- that's the fault of BIEL management for creating those unrealistic expectations.
Next year the CMS is going to get blamed for BIEL's products not qualifying for Medicare reimbursement and the FDA is going to get blamed for not acting fast enough to clear the new "higher-power" device and Big Pharma is going to get blamed for keeping poor little mom-and-pop BIEL down and Ilfeld is going to get blamed for not completing a followup clinical study (He typically takes years to complete a full-scale clinical study).
Poor BIEL. Poor, poor BIEL. So persecuted. So mistreated.
RecoveryRx also lasts 720 hours. They didn't extend its life. It's the same device and battery as ActiPatch.
Name one opportunity they can pursue without having any money.
Because they have no money.
Yes, they were amateurs to sign that KT Tape deal, but they have nothing with which to replace the KT Tape deal.
As if comparing BIEL to Microsoft or AOL or Time Warner was even slightly appropriate.
Sorry but that BS doesn't merit discussion. Your bashing of KT Tape, however, does merit discussion -- so I was discussing it.
Bashing KT Tape in hindsight is a neat trick. That's what I love about BIEL: their lack of sales is always someone else's fault.
Where was this criticism of KT Tape when BIEL was pumping their OEM Partnership with KT Tape as the road to riches?
And where are all the other OEM Partnerships? This business model was dependent on continuing to sign new OEM Partners, right?
A "major company" generates more than $158,000 in quarterly gross revenues. That's the number from the most recent reported quarter.
And $158,000 was a good quarter for BIEL. The previous two quarters' gross quarterly revenues were $48,000 and $55,000.
YTD 2022 gross revenues were only $652,043. Do you think $652,043 in gross annual revenues identifies a "major company?"
We're about to see the 2023 YTD numbers -- how much gross annual revenues do YOU think a company needs to generate post-pandemic to be called a "major company?"
Apparently you think that being in a "brand new field in the public's eye" identifies a company as a "major company." AI is a brand new field -- by your definition, every company in AI is a "major company." There are some pretty sketchy companies in AI, but in your mind they are all "major companies." Huh.
But we digress. What is BIEL doing to prepare for the NOPAIN Act?
And what is BIEL doing in preparation for the NOPAIN Act?
If you can't attack the message, attack the messenger.
It's called the Ad Hominem fallacy.
Every time you reply to one of my posts, you prove my point by failing to refute it and attacking me instead. You realize that, right?
Is the NOPAIN Act really the next catalyst?
You realize that's not even starting until 2025.
And you realize that nobody knows whether the CMS will approve the ActiPatch/RecoveryRx for Medicare reimbursement. There is currently no clinical proof that the device reduces opioid use. Ilfeld's pilot study MIGHT satisfy this requirement, and it might not.
Sorry, but the Lord o' the Charts is pumping that BIEL is going to skyrocket because his TA tells him so.
THAT is BS.
Regarding "One Big Deal" -- True Longs (aka bagholders) have been waiting for that "One Big Deal" for how long? And the fact that it never comes doesn't suggest that it's never coming?
And "Everyone knows what catalysts are in play for 2024?" Can you list them? The phantom pain study publication was supposed to be one of them, wasn't it?
Here's my list of 2024 catalysts:
* Ilfeld's Phantom Pain pilot study -- it happened. Notice the effect on the PPS.
* Financial report in three weeks (or lack of it)
* Acknowledgement that the Sales VP departed last June and has not been replaced
* Funding (R/S?)
* Completion of Ilfeld's opioid pilot study.
* Publication of Ilfeld's opioid pilot study (likely in 2025)
* Stanford clinical trial finishes.
* "Expedited 510(k)" submitted for the Higher-powered device? Maybe in 2024.
Which of those do you think will cause anything other than a blip on the chart? If history is any indication -- and we all know it is -- every bit of good news will be met with massive selling pressure. And how much of that is actually "good news?"
Maybe the Lord o' the Charts will be able to flip those 2's he says he just bought. Good for him. Flippers rule. LOL
Financial report in three weeks.
Funding.
I'm predicting a reverse split because I honestly don't see how they will get funding any other way. The COB has been lending the company money for a couple of years but if you read his year-end press release I think you'll agree that he is telling shareholders there has to be more funding than his checkbook.
in three weeks, BIEL will either release 2023 financials or go to Expert Market.
Here are the numbers from Q1 2023. To calculate numbers for quarters 2, 3, and 4 combined, subtract these from the year-end numbers.
Sales: $158,077
Net Loss: $209,354
Debt (Total Liabilities): $16,135,333
FYI, there will be no way to calculate quarter-by-quarter numbers.
Well said.
Add to that: BIEL 2024 is nothing like BIEL 2021.
Night and day difference between BIEL 2024 and BIEL 2021.
the Master O' Charts stated in detail how he's flipped BIEL three times in the past three years. You and the rest of the Chimps in the primate cage are so critical of flippers. Are you and the Chimps going to abuse, ridicule, and mock the ChartMaster for his flipping?
Or does he get a free pass because he pumps BS?
I'm sorry that I gave you the impression that I care about your BS.
Save it for your "Followers."
You're taking credit for all those biotechs getting manipulated in Feb 2021?
LOL that's pretty funny. Do your followers think those stocks exploded in February 2021 because YOU said they would? Do they think TA had ANYTHING to do with that?
Do you practice saying "I am Chart-Master" in the mirror? Do you thump your chest while doing so?
Tell me how your "Follower" scheme works. You buy BIEL at .0002 and sell to your followers at .0003 or .0004? How often do they fall for this?
We went over this last year. We all made money trading OTC biotechs in 2021 because every OTC biotech was manipulated in 2021 -- that wasn't TA, that was just playing the OTC biotech game.
It's happened since sporadically on a few OTC biotechs, but not on turds like BIEL.
And people who actually make $1.9 million trading OTC stocks don't talk about it on message boards. Winners don't brag about winning. Losers lie about winning though.
You acknowledge that when you pumped this in 2023 you lost money.
You think having Followers on iHub gives a person "Cred" in this life? How sad.
LOL prepare yourself for abuse because you're acknowledging that you're a FLIPPER. I applaud you for making money on this stock but then again I have no "Cred." LOL
News flash: TA doesn't work on zombie biotechs.
Best of luck with your pump, but it didn't work last June so I don't know why you think it will work now.
Financial report in three weeks and it's not going to be pretty. In addition to the bad numbers, Whelan will finally have to disclose that Nalepka the Sales VP left the company last June and hasn't been replaced. Whelan is the only Officer left at the company.
Those .0002's you just bought might not look so sweet after the reverse split that we all know is coming. You left the R/S off your list of "catalysts." Will Whelan disclose the timing of the R/S when she files the financials?
You also left the $14 million lawsuit against Mundipharma off your list of "catalysts." And don't forget the $10 million Synergy Deal. Better go back and add those. If you're going to pump BS, you might as well be thorough.
"Chartists," LOL
that's you pumping on FB, isn't it.
News flash: TA doesn't work on zombie biotechs.
Best of luck with your pump, but it didn't work last June so I don't know why you think it will work now.
Financial report in three weeks and it's not going to be pretty. In addition to the bad numbers, Whelan will finally have to disclose that Nalepka the Sales VP left the company last June and hasn't been replaced. Whelan is the only Officer left at the company.
Those .0002's you just bought might not look so sweet after the reverse split that we all know is coming. You left the R/S off your list of "catalysts." Will Whelan disclose the timing of the R/S when she files the financials?
You also left the $14 million lawsuit against Mundipharma off your list of "catalysts." And don't forget the $10 million Synergy Deal. Better go back and add those. If you're going to pump BS, you might as well be thorough.
"Chartists," LOL
Chartmaster, remember when you were pumping BIEL back in June 2023 when the pps was .0005 - .0007??
Read the thread to which I'm replying here.
Looks like your Charts didn't foretell the future last June. Did you sell for a loss, or are you still holding that bag?
Also, Synergy was not a "major distributor."
Synergy was one guy wearing sandals in Kathmandu. He had an office in the basement of some building with one desk, one chair, a sign.
https://www.google.com/maps/place/Synergy+Corporation/@27.7213319,85.3337148,3a,75y,90t/data=!3m8!1e2!3m6!1sAF1QipMCR0vmROTLg4AqKZTUTUduI2kNDkEJgye1hlIp!2e10!3e12!6shttps:%2F%2Flh5.googleusercontent.com%2Fp%2FAF1QipMCR0vmROTLg4AqKZTUTUduI2kNDkEJgye1hlIp%3Dw86-h188-k-no!7i1824!8i4000!4m7!3m6!1s0x39eb198f0e4076bf:0xdfcb2c9cd7f11f7c!8m2!3d27.7213591!4d85.333638!10e5!16s%2Fg%2F11h2qtcdh6?authuser=0&entry=ttu
He also had the gift of gab, apparently. He talked that KitoTech owner into releasing a PR. Remember how KitoTech used a fake Synergy logo on LinkedIn?
https://www.prweb.com/releases/kitotech-medical-inc-signs-agreement-with-synergy-corporation-for-international-distribution-of-their-medical-and-consumer-products-803148643.html
it's all speculation because this company lacks transparency. Nobody knows what was in the MundiPharma agreement and nobody knows what was in the Synergy agreement.
It's pretty safe speculation, though, that:
* No company -- not MundiPharma, not ANYONE -- would promise a little company like BIEL a contractually obligated payment of $14 million for a new product that has no proven sales success anywhere on the globe. That's simply not done.
* Because BIEL didn't promote it as a contractual purchase order for $14 million at the time it was signed, it's likely that it WASN'T a contractual purchase order. That would have been HUGE NEWS if true.
Read the original MundiPharma PR's from 2018.
https://www.bielcorp.com/bioelectronics-actipatch-musculoskeletal-therapy-added-to-mundipharma-australias-pain-portfolio/
https://www.globenewswire.com/en/news-release/2018/11/15/1652277/0/en/BioElectronics-Signs-a-Five-Country-Additional-Distribution-Agreement-with-Mundipharma-Pty-Limited-South-East-Asia.html
All they say is that MundiPharma "[acquired] the distribution rights in South East Asia, for Singapore, Malaysia, Thailand, Indonesia and the Philippines." That is a Distribution Agreement. There's no hint in these PR's that MundiPharma contractually promised to purchase anything, not in Australia, not in SE Asia, not anywhere. That would have been SO MUCH BIGGER than the Synergy story because Synergy was an unknown sketchy little company in Nepal -- nobody really believed THAT story because it didn't look like Synergy had any money. They couldn't even pay to maintain their website. MundiPharma, on the other hand, might have been able to come up with $$$ millions.
Here's an idea. Contact BIEL and tell them you want to invest in their litigation against MundiPharma. They would HAVE to let you see that contract because of course you wouldn't give them money without having your lawyer examine that contract and determine the likelihood of winning.
Be sure to ask for any amendments.
Mundi Pharma is not related to Synergy. Whelan may have been "duped" by both, but if so, they were separate "dupings."
Regardless, I don't believe that either MundiPharma or Synergy contractually promised to buy ANYTHING. They were both just distribution agreements, IMO, which means there's no "Breach of Contract" for lack of purchases and no legal recourse for BIEL.
That lawsuit will never happen, IMO. Anyone considering funding BIEL's lawsuit against MundiPharma would insist on reading the contract, and there's no way MundiPharma contractually promised to buy $14 million worth of product without knowing whether they could sell it or not. They wouldn't contractually promise to buy $1.4 million worth of product, let alone $14 million -- nobody would. It's absurd. So BIEL is never going to get funding for that lawsuit.
And if BIEL raises money some other way and wastes it on a David-vs-Goliath lawsuit against MundiPharma (in Singapore of course), that would be a travesty. They need the money for other things and MundiPharma would effortlessly wear BIEL down with delays and legal maneuvers.
"Why did Bioelectronics Incorporated let their patents expire?"
That's what I asked Bing AI. Here's what Bing AI said:
Bing AI is bullshit -- let's not pretend it's anything else.
You can influence the answer by the phrasing and words used in your "question." Example:
Ask Bing AI "Is Bioelectronic Incorporated a good investment?" and you get this non-information:
ddls, just put me on Ignore. I think you're a fool with nothing of substance to say. I don't want to see your replies. Please spend your time bothering someone else.
You have me confused with someone else. I haven't bought BIEL since 2020.
Looking back in my trading spreadsheet:
Bought and sold BIEL in 2015 and made some decent money.
Bought some in 2018-2019 and made decent money selling July 2019 and Feb 2020
Bought some in April 2020, sold it in June 2020 for a loss, selling the entire position
Have not bought BIEL since, currently own zero
And it was never 1-2 million "flips."
So it's YOU, sir, who are full of bullshit.
And I don't know what "admitted flipper" means to you, but if I buy a biotech stock and a PR comes out the next day and I can sell for a decent profit, I'll absolutely sell. If that makes me an "admitted flipper," then fine, I'm an "admitted flipper." One of the basic rules of pennystock biotech is "sell the news." You haven't learned the rules yet even though you've been pumping this since 2014.
The word for me is "trader." The word for you is "bagholder."
YOU'RE asking ME "why bother?"
I am not trying to influence anyone. I'm not trying to flip this stock. I simply like to talk about BIEL because I've been studying this stock and company for ten years. I like to point out the negatives because the pumpers here make me nauseous with their bullying, smugness, and ignorance, but if I see positives I point those out because the facts are the facts. Unless you're claiming that Ilfeld invented that data, you have to admit that his study results are impressive. Granted, the study is underpowered and it's just a pilot study, but those results are impressive nonetheless.
This company is not a scam. It's a small mom-and-pop operation with inexperienced management, and the device is dubious -- some clinical trials show that it DOESN'T work and some trials show that it DOES work. The ActiPatch absolutely did not work at all for me when I tried two of the devices. Nobody can explain the science of why it works for some but not for others, and that bothers me. But it's NOT a scam.
The biotech highway is littered with the corpses of biotechs that got FDA approval only to discover that they couldn't sell the product. This looks like just another zombie, but it's still staggering along.
The "hickory heads" are those who believe that everyone posting on message boards is trying to manipulate the stock, one way or another. Sorry, but that describes you. You have an agenda, fine, but that's YOUR problem, not mine, and it follows that my LACK of agenda is not your problem. So put me on ignore as I did for you years ago, and stop replying to my posts because you never have anything of substance to say -- you're every bit as useless as JGD.
Art, Art, Art. Phantom pain absolutely DOES exist.
I think you might not understand what pain is and what causes it. Case in point: after a collision in the outfield chasing a fly ball, I had a feeling in my rib cage like someone was stabbing an ice pick into my chest. My GP told me I had a bruised rib but ice packs to my rib cage and tylenol didn't help much. I had to go to a chiropractor to learn that the problem was actually a bulging disk in my neck, pressing on a nerve.
Amputee phantom pain is similar. A nerve somewhere in the leg (or maybe even in the spine) is telling the patient that there's a pain in a limb where there is no longer a limb. It's still pain. It DOES exist.
Regarding Ilfeld's work: he will now probably get funding for, and conduct, a larger scale clinical study for PEMF treatment of phantom pain. It will probably take years, judging from how long his other studies take. The indication of phantom limb pain isn't going to make anyone rich but I don't think anyone is claiming that. Illfeld's interest in PEMF is certainly a positive development for this company.
What's wrong with that Form 4?
Do you understand it, or do you need an explanation? Are you filled with FUD about that Form 4 because you think that Imhoff is not really a Director or not really a person? Or have you given up on that line of BS? Do you remember when you claimed there was no evidence that any of the Directors were real people?
Do you know what "precipitously" means?
Do you remember how many times you claimed the PPS could not and would not get as high as 15 cents? You went off on THAT tirade for months.
Isn't it time to bring on your other alias to have a fake conversation with yourself, creating the illusion that SOMEONE agrees with you?
It's a good sign that the company ponied up and released a legitimate PR.
History of GTHP for new investors - a primer
Of course, everyone does their own exhaustive DD before they buy a stock, but if any new investors want the Cliff notes:
GTHP got their 3rd FDA rejection in April 2015. Here's the PR:
https://www.otcmarkets.com/stock/GTHP/news/FDA-Completes-Review-of-Guided-Therapeutics-LuViva-Advanced-Cervical-Scan-PMA-Application?id=105061
The PR doesn't seem all that negative as FDA rejections go, but this rejection caught GTHP by surprise. Plan A was to get the PMA approval and get financing, so when the PMA was rejected they had no money and no plan B. The company fell into toxic death spiral financing with a couple of VERY shady lenders (One of which got into trouble with the SEC and caused them to dump in June 2023 but that's a different story). There was a 1:100 R/S in Feb 2016 and when the PPS tanked there was another R/S, this time 1:800, in 11/2016, but the PPS tanked even harder after that second R/S.
The company had no money and frankly not much hope of surviving, but somehow, Cartwright the CEO managed to get rid of the toxic lenders over the next few years. The company re-established communication with the FDA in 07/2017 and when they did the most recent R/S in March 2019, the resulting PPS of 15 cents has held.
They managed to get funding for a new clinical study, and it's coming to completion:
https://clinicaltrials.gov/study/NCT04915495
Notice I didn't mention SMI. I will believe the China Hype when GTHP gets a sizable check. If you read all the China PR's I think you'll agree that SMI has failed to fulfill their promises time and time again. The good news is that the China clinical study with 400 participants was apparently completed and was successful; that will bolster GTHP's amended PMA when they submit.
I have no doubt that the US clinical trial will be successful and that GTHP will submit the amended PMA. After that, it's hard to say how long the FDA will take to review the PMA, but it's an amended PMA, not a brand new submission. I also never assume any FDA submission is a slam dunk, but in my opinion, this is as close to a slam dunk as it gets.
I'm not sure why our resident basher is trying so hard to raise FUD. My only guess is that he held after that 2015 FDA rejection, which is something I've learned not to do -- yes I lost money in 2015 but I accept the risk of FDA plays, so I sold my entire position the day after that PR, took my loss, and moved on, watching and waiting. If our basher held, the R/S's in 2016 reduced his position to ashes, which I guess would make anyone bitter.
When that 2019 R/S held its resulting 15 cents, I started getting back in. It's not common for a pennystock developmental biotech hold its price after a R/S. It's SUPER uncommon. Our resident basher thinks the PPS should be at $5 but I'm surprised it didn't fall to a penny after that 3rd R/S.
So here we are, close to the milestone of completing that clinical trial and submitting the PMA. It would be nice if SMI mails a check because GTHP has to be out of cash by now, so I expect some bridge financing if SMI doesn't pony up. $500,000 from SMI in March would be a godsend, IMO, but again, I'll believe it when the check clears.
Also of note: it's important to know that the giul lawsuit against shenghuo does not name GTHP as a defendant. The lawsuit started in 2019 and originally it did name GTHP, but the company has since been removed from the lawsuit.
Cheers.
Ilfeld's post-amputation study published -- Positive results:
https://rapm.bmj.com/content/early/2024/02/21/rapm-2023-105154?fbclid=IwAR2xW_VH5mGdZeTSWI_xzTmitk2GdOMBFftbNp841lGb5rhyGOaHLp9gybs
You win. You've worn me down with bullshit. I can no longer read your nonsense. Congratulations! You now have an audience of zero.
See, you never answer a question or defend your opinion. You don't engage in a discussion or debate. You just keep banging a pot and shouting nonsense.
"Your challenge" is for someone to slap the ask and drive the PPS from 15 cents to $1 or $3 or $5 without news. That's absurd. An increase to $1 is a 600% increase. How often do you think that happens in pennystock biotech? Without news, the answer is "never." Even with news, a 600% increase is uncommon. Your "respectable $5" would be a 3000% increase. And if that doesn't happen, this stock is dead and will never rise above 15 cents, in your opinion. That's what you've stated over and over, even when it does rise above 15 cents, and you'll keep shouting that until, when, the PPS hits $5.00 ?
Oh joy.